^
Association details:
| Biomarker: | CASP3 underexpression + BCL2 positive |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Regimen: | ABVD (bleomycin + dacarbazine + doxorubicin hydrochloride + vinblastine) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ACTIVATED CASPASE-3 EXPRESSION BY HODGKIN AND REED-STERNBERG CELLS (HRS) IS A POWERFUL PROGNOSTIC FACTOR IN CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ABVD OR EQUIVALENT REGIMENS
Published date:
05/17/2018
Excerpt:
Eligible patients had biopsy-proven cHL treated with ABVD or equivalent regimens….The 20-year FFP for patients whose tumors were aC3high/BCL2neg, either aC3low or BCL2pos, and aC3low/BCL2pos was 91% vs 84% vs 60% (p<0.0001)....The combination aC3low/BCL2pos defined a sizeable (~43% of patients) subgroup of advanced cHL with very poor outcome reflected by PFS<50%.
